Obstetrics & Gynaecology Search
Obstetrics & Gynaecology Obstetrics & Gynaecology
heavy%20menstrual%20bleeding
HEAVY MENSTRUAL BLEEDING
Heavy menstrual bleeding is prolonged (>7 days) or excessive (>10 mL) uterine bleeding occurring at regular intervals over several menstrual cycles.
It is menstrual blood loss that is excessive and interferes with patient's physical, emotional, social and quality of life.
It is also referred to as menorrhagia or hypermenorrhea.
It is a common problem in women of reproductive age that usually causes anemia.
Uterine fibroids and polyps are the most common pathology identified.

Heavy Menstrual Bleeding Drug Information

Drug Information

Indication: Emergency postcoital contraception.

Indication: Premenstruation syndrome, postponement of menstruation, mastodynia, cycle disturbance associated w/ shortening...

Indication: Emergency postcoital contraception.

Indication: OC.

Indication: Hemorrhagic diseases & abnormal bleeding. Allergic & inflammatory symptoms.

Indication: Relief of fever & mild to moderate pain including headache, dental pain, post-op pain, dysmenorrhoea; musc...

Indication: Primary dysmenorrhea & relief of moderate pain when therapy will not exceed 1 wk.

Indication: Prevention of pregnancy. Moderate acne vulgaris not controlled by conventional therapy eg, topical prep & ...

Indication: Mild to moderate muscular, traumatic & dental pain, headache, post-op & post-partum pain, RA (includin...

Indication: Prevention of pregnancy.

1  /  4
1  /  4
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Novel non-hormonal therapy may reduce hot flashes, improve QoL in postmenopausal women
Roshini Claire Anthony, 21 Oct 2020

NT-814, an oral, non-hormonal dual neurokinin 1,3 receptor antagonist may reduce the frequency of hot flashes, while improving quality of life (QoL) and sleep in postmenopausal women, according to results of the phase IIb SWITCH-1 trial presented at NAMS 2020.